Pharmaceutical

Callio raises $187m for proof-of-concept for dual-payload ADC

Callio Therapeutics has raised $187m in Series A financing round for achieving clinical proof-of-concept for HER2-targeted dual-payload ADC.

Mar 5, 2025 - 06:00
Callio raises $187m for proof-of-concept for dual-payload ADC
Callio Therapeutics has raised $187m in Series A financing round for achieving clinical proof-of-concept for HER2-targeted dual-payload ADC.
Read the original article

Tags:

Previous Article

Antibody drug conjugates: Tackling the unsolved challenges with novel technologies

Next Article

Are European biopharma manufacturers ‘nearshoring’?

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

NHS rolls out “more convenient” Ocrevus injection for multiple sclerosis

NHS rolls out “more convenient” Ocrevus injection for m...

Jul 14, 2024

FDA lifts clinical hold on Avidity’s lead antibody conjugate therapy trial

FDA lifts clinical hold on Avidity’s lead antibody conj...

Oct 6, 2024

Why many more people are lining up for a flu shot than a Covid vaccine

Why many more people are lining up for a flu shot than ...

Jan 22, 2024